1[1]Holmer E,et al.Heparin and its Low Molecular Wejght Derivatives,anticoagulant and Antithrombotic Properties.Haenost,1986;16(supp1.2):1
2[2]Laforest MD.et al Pharmacokinetics and Biodistribution of Technetium 99m Labelled Standard Heparin and A Low Molecular Weight Heparin(enoxaparin)after Intravenous Injection in Normal Volunteers.Brit.J.Haematol.1991;77:201
3[3]Saivin S,et al.Pharmacodynamic Properies of Long Lasting Butyryl Heparin Derivatives in the Rabbit.Thromb.Haemost.1992:67(5):550
4[4]Bergonzini G,et al.01igo-Heparin Action on Endogenous Glycosaminoglycans.Pharmacokinetics:Direct and Mediated Effects.Semin.Thromb.Hemost.1994;20(3):274
5[5]Palm M and Mattsson C,Pharmacokinetics of Fragmin.A Comparative Study in the Rabbit of its High and Low Affinity Forms for Antithrombin,Thromd.Res.1987;48:51
6[8]Bergonzini Gl,et al.Different Pharmacokinetics,Antithrombotic Activity and Bleeding Effects of Heparin and Two New Fragments Administered in Rat by Subcutaneous Route.Arzneim.Forsch,1992;42(11):1322
7[9]Harenberg J,et al.Prophylasis of Embolic Events in Patients with Atrial Fibrillation Using Low Moleoular Weight Heparin,Semin.Thromb.Hemost.1993;19(suppl.1);116
8[10]Bacher PD,et all The Thrombolytic Potency of Low Molecular Weight Heparin Compared to Urokinase in A Rabbit Jugular Vein Clot Lysis Model.Thromb Res.192;66:151
9[11]Lojewski B,et al.Evaluation of Hematologic Alterations(Mono-Embolex)for A 12-Week Period.Semin.Thromb.Hemost.1993;19(suppl.1);36
